Plastic and nonmetallic article shaping or treating: processes – Encapsulating normally liquid material
Reexamination Certificate
2008-07-01
2008-07-01
Li, Q. Janice (Department: 1633)
Plastic and nonmetallic article shaping or treating: processes
Encapsulating normally liquid material
C264S004100, C264S004300, C424S450000
Reexamination Certificate
active
07393478
ABSTRACT:
A method for encapsulating cisplatin and other positively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers is disclosed. The liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans. The encapsulated cisplatin has a high therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the encapsulated cisplatin with encapsulated doxorubicin or with other antineoplastic drugs are claimed to be of therapeutic value. Also of therapeutic value in cancer eradication are claimed to be combinations of encapsulated cisplatin with a number of anticancer genes including but not limited to p53, IL-2, IL-12, angiostatin, and oncostatin encapsulated into liposomes as well as combinations of encapsulated cisplatin with HSV-tk plus encapsulated ganciclovir.
REFERENCES:
patent: 5213804 (1993-05-01), Martin et al.
patent: 5334761 (1994-08-01), Gebeyehu et al.
patent: 5393530 (1995-02-01), Schneider et al.
patent: 5567434 (1996-10-01), Szoka
patent: 5747469 (1998-05-01), Roth et al.
patent: 5795589 (1998-08-01), Mayer et al.
patent: 5843475 (1998-12-01), Perez-Soler et al.
patent: 5882679 (1999-03-01), Needham
patent: 5894060 (1999-04-01), Boulikas
patent: 5908777 (1999-06-01), Lee et al.
patent: 5945122 (1999-08-01), Abra et al.
patent: 6028066 (2000-02-01), Unger
patent: 6126966 (2000-10-01), Abra et al.
patent: 6511676 (2003-01-01), Boulikas
Boulikas, T., “A Unified Model Explaning the Preferential Repair of Active Over Inactive Genes and of the Transcribed Over the Nonstranscribed Strand: A Leading Role for Transcription Factors and Matrix Anchorage” Int. J. Oncol. 8:77-84 (1996).
Boulikas, T., “DNA lesion-recognizing proteins and the p53 connection” Anticancer Res. 16:225-242 (1996).
Boulikas, T., “Evolutionary consequences of nonrandom damage and repair of chromatin domains” J. Mol. Evol. 35:156-180 (1992).
Boulikas, T., “Nucleocytoplasmic trafficking: implications for the nuclear import of plasmid DNA during gene therapy” Gene Ther. Mol. Biol. 1:713-740 (1998).
Boulikas, T., “Nucleocytoplasmic Traffiking: Implications for the Nuclear Import of Plasmid DNA During Gene Therapy” Gen. Ther. Mol. Biol. 1:713-740 (1988).
Boulikas, T., “Status of gene therapy in 1997: Molecular mechanisms, disease targets, and clinical applications” Gene Ther. Mol Biol. 1:1-172 (1998).
Boulikas, T., “The Nonuniform Repair of Active and Inactive Chromatin Domains” Int. J. Onco. 8:65-75 (1996).
Decout, A. et al., “Contribution of the hydrophobicity gradient to the secondary structure and activity of fusogenic peptides” Mol. Membr. Biol. 16(3):237-246 (1999).
Duguid, J.G. et al., “A physiocochemical approach for predicting the effectiveness of peptide-based gene delivery systems for use in plasmid-based gene therapy” Biophys. J. 74:2802-2814 (1998).
Farhood, H. et al., “Cationic liposomes for direct gene transfer in therapy of cancer and other diseases” Ann. N.Y. Acad. Sci. 716:23-35 (1994).
Kim, J.C. et al., “Synthesis and antitumor evaluation of cis-(1.2-diaminoethane) dichloroplatinum (II) complexes linked to 5- and 6-methyleneuracil and -uridine analogues” Arch. Pharm. Res. 21(4):465-469 (1998).
Martin. F. and Boulikas, T., “The challenge of liposomes in gene therapy” Gene Ther. Mol. Biol. 1:173-214 (1998).
Martin, F. et al., “The Challenge of Liposomes in Gene Therapy” Gene Ther. Mol. Biol. 1:173-214 (1988).
Martin, L. and Ruysschaert, J-M., “Comparison of lipid vesicle fusion induced by the putative fusion peptide of fertilin (a protein active in sperm-egg fusion) and the NH2—terminal domain of the HIV2 gp41” FEBS Lett. 405(3):351-355 (1997).
Martin, L. et al., “Membrane fusion induced by a short fusogenic peptide is assessed by its insertion and orientation into target bilayers” Biochemistry 38(29):9337-9347 (1999).
Morikawa, K. et al., “Synthesis of platinum complexes of 2-aminomethylpyrrolidine derivatives for use as carrier ligands and their antitumor activities” Chem. Pharm. Bull. (Tokyo) 38(4):930-935 (1990).
Papadopoulou, M.V. et al., “NLCQ-1, a novel hypoxic cyctoxin: Potentiation of melphalan, cisDDP and cyclophosphamide in vivo” Int. J. Radiation Oncol. Biol. Phys. 42(4):775-779 (1998).
Pecheur, E.I. et al., “Membrane anchorage brings about fusogenic properties in a short synthetic peptide” Biochemistry 36(13):3773-3781 (1997).
Speelmans, G. et al. “The interaction of the anti-cancer drug cisplatin with phospholipids is specific for negatively charged phsopholipids and takes place at low chloride ion concentration” Biochim. Biophys. ACTA (1996) 1283:60-66.
Stathopoulos, G.P. et al., “Paclitaxel combined with cis-platin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cis-platin” Oncol. Rep. 6(4):797-800 (1999).
Zhang, M. et al. “Studies on Cisplatinum Alburnin Microspheres for Lung Targeting” Acta Pharmaccutica Sinica 29 (5):380-386 English Abstract on p. 386 (1994).
Foley & Lardner LLP
Hill Kevin K.
Li Q. Janice
Regulon, Inc.
LandOfFree
Therapy for human cancers using cisplatin and other drugs or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapy for human cancers using cisplatin and other drugs or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapy for human cancers using cisplatin and other drugs or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2813457